Teza Capital Management LLC Has $422,000 Stock Holdings in IQVIA Holdings Inc. $IQV

Key Points

• Teza Capital Management LLC reduced its stake in IQVIA Holdings Inc. by 49% during the first quarter, now holding shares valued at $422,000.
• Insider Eric Sherbet sold 5,800 shares of IQVIA stock, resulting in a 17.59% decrease of their ownership.
• Analysts have set varying price targets for IQVIA, with UBS Group raising their target to $225.00 and maintaining a "buy" rating.

Teza Capital Management LLC lessened its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 49.0% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,391 shares of the medical research company's stock after selling 2,300 shares during the quarter. Teza Capital Management LLC's holdings in IQVIA were worth $422,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. American National Bank & Trust acquired a new position in IQVIA in the first quarter valued at about $26,000. Clal Insurance Enterprises Holdings Ltd lifted its stake in IQVIA by 436.7% in the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company's stock valued at $28,000 after buying an additional 131 shares during the period. Golden State Wealth Management LLC increased its holdings in shares of IQVIA by 295.5% in the first quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock worth $31,000 after acquiring an additional 130 shares in the last quarter. AllSquare Wealth Management LLC bought a new stake in shares of IQVIA in the first quarter worth about $33,000. Finally, ST Germain D J Co. Inc. increased its holdings in shares of IQVIA by 66.1% in the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock worth $34,000 after acquiring an additional 76 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.

Insider Buying and Selling at IQVIA

In other IQVIA news, insider Eric Sherbet sold 5,800 shares of the stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the sale, the insider owned 27,178 shares in the company, valued at $5,165,178.90. This represents a 17.59% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Keriann Cherofsky sold 549 shares of the stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the completion of the sale, the insider owned 2,910 shares in the company, valued at $557,352.30. This trade represents a 15.87% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 1.60% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on IQV. JPMorgan Chase & Co. decreased their price objective on IQVIA from $232.00 to $177.00 and set an "overweight" rating for the company in a report on Monday, May 19th. Redburn Partners set a $214.00 price objective on IQVIA in a research report on Wednesday. UBS Group lifted their price target on IQVIA from $185.00 to $225.00 and gave the stock a "buy" rating in a report on Wednesday, July 23rd. Robert W. Baird raised their price objective on IQVIA from $159.00 to $196.00 and gave the stock a "neutral" rating in a research note on Wednesday, July 23rd. Finally, Barclays raised their price objective on IQVIA from $165.00 to $185.00 and gave the stock an "equal weight" rating in a research note on Wednesday, July 23rd. Seventeen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $229.86.

IQVIA Stock Up 2.0%

IQV stock opened at $187.75 on Monday. The stock's 50 day simple moving average is $179.88 and its 200 day simple moving average is $167.23. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $249.43. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84. The company has a market cap of $31.92 billion, a P/E ratio of 27.17, a price-to-earnings-growth ratio of 2.06 and a beta of 1.32.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, topping analysts' consensus estimates of $2.77 by $0.04. The firm had revenue of $4.02 billion during the quarter, compared to analyst estimates of $3.96 billion. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The company's revenue for the quarter was up 5.3% on a year-over-year basis. During the same period in the previous year, the company posted $2.64 EPS. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. On average, research analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.